372 related articles for article (PubMed ID: 17456614)
1. Kaposi's sarcoma in renal transplant recipients--the impact of proliferation signal inhibitors.
Campistol JM; Schena FP
Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i17-22. PubMed ID: 17456614
[TBL] [Abstract][Full Text] [Related]
2. Use of proliferation signal inhibitors in the management of post-transplant malignancies--clinical guidance.
Campistol JM; Albanell J; Arns W; Boletis I; Dantal J; de Fijter JW; Mortensen SA; Neumayer HH; Øyen O; Pascual J; Pohanka E; Schena FP; Serón D; Sparacino V; Chapman JR
Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i36-41. PubMed ID: 17456617
[TBL] [Abstract][Full Text] [Related]
3. Post-transplant lymphoproliferative disorder--the potential of proliferation signal inhibitors.
Pascual J
Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i27-35. PubMed ID: 17456616
[TBL] [Abstract][Full Text] [Related]
4. Use of proliferation signal inhibitors in non-melanoma skin cancer following renal transplantation.
de Fijter JW
Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i23-6. PubMed ID: 17456615
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of conversion to sirolimus in posttransplantation Kaposi's sarcoma.
Gutiérrez-Dalmau A; Sánchez-Fructuoso A; Sanz-Guajardo A; Mazuecos A; Franco A; Rial MC; Iranzo P; Torregrosa JV; Oppenheimer F; Campistol JM
Transplant Proc; 2005 Nov; 37(9):3836-8. PubMed ID: 16386556
[TBL] [Abstract][Full Text] [Related]
6. A novel immunosuppressive agent, sirolimus, in the treatment of Kaposi's sarcoma in a renal transplant recipient.
Yilmaz R; Akoglu H; Kirkpantur A; Kilickap S; Arici M; Altun B; Aki T; Erdem Y; Yasavul U; Turgan C
Ren Fail; 2007; 29(1):103-5. PubMed ID: 17365918
[TBL] [Abstract][Full Text] [Related]
7. Everolimus in clinical practice--renal transplantation.
Pascual J
Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii18-23. PubMed ID: 16815852
[TBL] [Abstract][Full Text] [Related]
8. Sirolimus for Kaposi's sarcoma in renal-transplant recipients.
Stallone G; Schena A; Infante B; Di Paolo S; Loverre A; Maggio G; Ranieri E; Gesualdo L; Schena FP; Grandaliano G
N Engl J Med; 2005 Mar; 352(13):1317-23. PubMed ID: 15800227
[TBL] [Abstract][Full Text] [Related]
9. Kaposi's sarcoma and mTOR: a crossroad between viral infection neoangiogenesis and immunosuppression.
Stallone G; Infante B; Grandaliano G; Schena FP; Gesualdo L
Transpl Int; 2008 Sep; 21(9):825-32. PubMed ID: 18498314
[TBL] [Abstract][Full Text] [Related]
10. Regression of Kaposi's sarcoma in renal graft recipients after conversion to sirolimus treatment.
Zmonarski SC; Boratyńska M; Rabczyński J; Kazimierczak K; Klinger M
Transplant Proc; 2005 Mar; 37(2):964-6. PubMed ID: 15848592
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment of post-renal transplant gastric and pulmonary Kaposi's sarcoma with conversion to rapamycin treatment.
Charfi S; Krichen-Makni S; Yaich S; Makni H; Khabir A; Amouri A; Charfeddine K; Hachicha J; Sellami-Boudawara T
Saudi J Kidney Dis Transpl; 2007 Nov; 18(4):617-20. PubMed ID: 17951954
[TBL] [Abstract][Full Text] [Related]
12. Regression of post-transplant Kaposi's sarcoma using sirolimus.
Kolhe N; Mamode N; Van der Walt J; Pattison J
Int J Clin Pract; 2006 Nov; 60(11):1509-12. PubMed ID: 16787440
[TBL] [Abstract][Full Text] [Related]
13. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?
Rostaing L; Kamar N
J Nephrol; 2010; 23(2):133-42. PubMed ID: 20155724
[TBL] [Abstract][Full Text] [Related]
14. Complete regression of visceral Kaposi's sarcoma after conversion to sirolimus.
Mohsin N; Budruddin M; Pakkyara A; Darweesh A; Nayyer M; Amitabh J; Daar AS
Exp Clin Transplant; 2005 Dec; 3(2):366-9. PubMed ID: 16417445
[TBL] [Abstract][Full Text] [Related]
15. Conversion to a proliferation signal inhibitor in a patient with coronary artery disease--a case report.
Sparacino V; Calabrese S
Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii34-7. PubMed ID: 16815856
[TBL] [Abstract][Full Text] [Related]
16. Clinical recommendations for the use of everolimus in heart transplantation.
Manito N; Delgado JF; Crespo-Leiro MG; González-Vílchez F; Almenar L; Arizón JM; Díaz B; Fernández-Yáñez J; Mirabet S; Palomo J; Rodríguez Lambert JL; Roig E; Segovia J
Transplant Rev (Orlando); 2010 Jul; 24(3):129-42. PubMed ID: 20619801
[TBL] [Abstract][Full Text] [Related]
17. Potential role of proliferation signal inhibitors on atherosclerosis in renal transplant patients.
Andrés V; Castro C; Campistol JM
Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii14-7. PubMed ID: 16815851
[TBL] [Abstract][Full Text] [Related]
18. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology.
Valantine H
J Heart Lung Transplant; 2007 Jun; 26(6):557-64. PubMed ID: 17543777
[TBL] [Abstract][Full Text] [Related]
19. [Replacing calcineurin inhibitors with proliferation signal inhibitors after kidney transplantation: indications, results, and disadvantages].
Audard V
Nephrol Ther; 2009 Dec; 5 Suppl 6():S395-9. PubMed ID: 20129452
[TBL] [Abstract][Full Text] [Related]
20. Late conversion to mammalian target of rapamycin inhibitor/proliferation signal inhibitors in kidney transplant patients: clinical experience in the last 5 years.
Sola E; Lopez V; Gutierrez C; Cabello M; Burgos D; Molina MG; Hernandez D
Transplant Proc; 2010 Oct; 42(8):2859-60. PubMed ID: 20970551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
